Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of March 2026. The report details a corporate action involving the grant of employee warrants and an amendment to the Company's Articles of Association.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on equity compensation terms.
Material Changes
- Warrant Grant: On March 10, 2026, the Board of Directors granted 22,480 warrants to certain employees.
- Exercise Price: The exercise price is set at US $240.52 per share, based on the closing price of the American Depositary Shares (ADS) on the grant date.
- Vesting Schedule: 25% of the warrants vest on the one-year anniversary of the grant date. The remaining 75% vest monthly at a rate of 1/36th thereafter, subject to continued service.
- Remaining Pool: Following this grant, 1,644,153 warrants remain available for future grants under the Articles of Association.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are disclosed in this report, other than the standard vesting conditions tied to continued service and potential exit events.
Investor Verification Checklist
- Verify the total number of outstanding warrants and the remaining pool size (1,644,153) in the updated Articles of Association.
- Confirm the impact of the 22,480 new warrants on potential future dilution.
- Review the specific terms of the "exit events" that could trigger earlier vesting of the warrants.
- Check subsequent filings for any financial results or updates not included in this specific Form 6-K.